Company intelligence / Profile preview

Cantheon Capital

Dallas, Texas, United States

Ownership: Private
Development stage: Other

Overview

Cantheon Capital is a venture capital firm headquartered in Dallas, Texas, specializing in investing in early and mid-stage biotechnology and pharmaceutical companies, with a particular focus on cannabinoid and psychedelic drug developers. The firm provides capital, corporate advisory, and scientific advice, targeting companies with near-term catalysts for value creation.

Modalities: Small moleculeCannabinoid drugPsychedelic drug
Industry: Investors

Partnerships

Psyence Group (Investment partnership for Phase IIb clinical trial of natural psilocybin in palliative care)Albert Labs (Strategic investment supporting psychedelic research)iNGENū (Clinical trial partnership via Psyence Group in Australia)

Beyond the preview

Go deeper on Cantheon Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cantheon Capital.

Explore the full profile